肾动脉狭窄 中国就医指南

Renal artery stenosis (RAS) is a narrowing of one or both renal arteries—the major blood vessels supplying oxygenated blood to the kidneys. This condition impairs renal perfusion, triggering activation of the renin-angiotensin-aldosterone system (RAAS), which can lead to secondary hypertension and progressive chronic kidney disease. The two primary pathogenic mechanisms are atherosclerotic RAS—accounting for over 90% of cases in adults over 50—and fibromuscular dysplasia (FMD), a non-inflammatory, structural vascular disorder more common in younger women under 50. Atherosclerotic RAS typically affects the proximal segment of the main renal artery and is strongly associated with systemic atherosclerosis, while FMD often involves the mid-to-distal arterial segments and presents with a characteristic 'string-of-beads' angiographic appearance. Epidemiologically, RAS prevalence rises sharply with age: it affects approximately 5–10% of adults aged 65–75 years and up to 18–42% of those over 75, particularly among patients with coronary or peripheral artery disease. Key risk factors include advanced age, smoking, hypertension, diabetes mellitus, hyperlipidemia, chronic kidney disease, and a history of cardiovascular disease. Notably, RAS is underdiagnosed—many patients remain asymptomatic until significant renal ischemia or refractory hypertension develops. Clinical manifestations may include sudden-onset or worsening hypertension (especially diastolic or resistant to ≥3 antihypertensives), episodic pulmonary edema, unexplained decline in glomerular filtration rate (GFR), flash pulmonary edema, or recurrent congestive heart failure. Quality of life is substantially impacted: patients frequently experience fatigue, anxiety related to uncontrolled blood pressure, medication burden, reduced physical stamina, and fear of dialysis or cardiovascular events. Untreated severe RAS increases risks of accelerated hypertension, ischemic nephropathy, end-stage renal disease, myocardial infarction, and stroke. Early detection via duplex ultrasonography, CTA, MRA, or captopril renography—combined with individualized risk-benefit assessment—is critical. While revascularization (angioplasty ± stenting) was historically pursued aggressively, landmark trials (e.g., CORAL, STAR) demonstrated that optimal medical therapy—including RAAS inhibition (when safe), statins, antiplatelets, and strict BP and metabolic control—remains first-line for most patients. Revascularization is now reserved for select cases: hemodynamically significant stenosis with acute pulmonary edema, rapidly deteriorating renal function, or unilateral RAS with renovascular hypertension unresponsive to maximal medical therapy. Multidisciplinary management involving nephrologists, interventional radiologists, and cardiologists ensures personalized, evidence-based care and improved long-term outcomes.

# 肾动脉狭窄治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：轻度狭窄（<50%）、无明显肾功能恶化或高血压难控者，或高龄/合并严重基础病不宜介入者。

• •药物治疗：ACEI/ARB（如缬沙坦）、CCB（氨氯地平）、他汀、抗血小板（阿司匹林）

• •监测与检验：肾动态显像（99mTc-DTPA）、肾动脉超声、血肌酐/eGFR、24h尿蛋白定量

二、手术/介入治疗方案

适用人群：中重度狭窄（≥70%）、难治性高血压、进行性肾功能下降或单肾动脉狭窄。

• •肾动脉支架置入术（首选）：经股/桡动脉入路，覆膜/裸金属支架

- 手术总费用（含支架、耗材、麻醉、住院7天）：85,000–145,000元（国产支架 vs 进口药物涂层支架）

三、特殊复杂情况方案

适用人群：纤维肌性发育不良、多发性大动脉炎累及肾动脉、支架再狭窄、双侧同步病变或终末期肾病合并顽固高血压。

• •多学科联合管理（肾内科+血管外科+风湿免疫科）+个体化免疫抑制（如糖皮质激素+环磷酰胺）或再次介入/搭桥术

四、方案快速选择指南

• •预算有限/稳定期患者 → 优选药物+规范随访（年支出≤8,000元）
• •中青年/进展性高血压/单侧优势肾 → 首选支架术（性价比最优，医保报销后自付约2.5–5万元）
• •大动脉炎活动期或支架失败 → 转入专科中心启动免疫调控+定制介入策略